This Is Already Being Administered —…

Q: How does the regulated pharmacy model handle diversion control?

It handles diversion control the same way other high-risk systems do: identity verification, limits, audits, and tightening protocols when risk rises. British Columbia's shift to witnessed dosing for prescribed alternatives is a real-world example of tightening to prevent diversion to illicit markets.

Q: What is the single biggest "do this first" recommendation?

Medication for opioid use disorder access. CDC's estimate that only 25% of adults needing OUD treatment in 2022 received medications should be treated as a national failure metric.

Q: How do you keep reforms from collapsing politically?

Pilot programs plus policy evaluation plus dashboards. Oregon's audit is a warning: if you can't show outcomes clearly, reform becomes a narrative war you lose.

DRUG LEGALIZATION SERIES
PART 19
If you’re new to the series, start here.

This Is Already Being Administered
The myth that regulation is too complex to run — and why that excuse is no longer credible.

Executive Summary

The most common “serious” argument against drug legalization is not that regulation can’t reduce harm.

It’s that regulation is too complex to administer.

That claim collapses the moment you look around.

We already administer complex, high-risk systems every day: controlled substance recordkeeping, pharmacy inventories, prescription drug monitoring programs, opioid treatment program rules, FDA risk-management programs, and a growing set of overdose prevention tools. The question is not whether the work is administrable. The question is whether we will administer it on purpose, with transparent goals and measurable outcomes.

In 2024, the United States recorded 79,384 drug overdose deaths.[1] Even with improvement, the baseline is still mass death. If someone argues regulation is “too hard,” they are implicitly defending the system we already administer — the one producing funerals.

This chapter argues for drug policy reform built as public health drug regulation: standards, monitoring, enforcement, and care access designed to reduce mortality and disorder. It also shows why “too complex” is usually a political excuse, not a technical barrier.

You will see five concrete points repeat:

• Public health drug regulation is already being administered in pieces; the missing step is aligning those pieces around overdose prevention, public safety, and accountability.
• The regulated pharmacy model is not a fantasy structure. It is an extension of systems pharmacies already operate under federal recordkeeping and inspection rules.[2]
• The strongest drug regulation case studies include OTP oversight, PDMPs, and FDA REMS programs — plus high-structure international models like Switzerland’s heroin-assisted treatment.[3][4][6][12]
• Medication for opioid use disorder access is the clearest proof that we can run complex systems — we’re just running them in ways that block care. In 2022, only 25% of adults needing OUD treatment received medications for OUD.[7]
• Harm reduction implementation is already happening (naloxone, syringe services programs). CDC summarizes decades of research showing comprehensive SSPs do not increase illegal drug use or crime.[8]

Assumptions (stated)

• Geographic focus is U.S.-centered, with Portugal, Switzerland, and Canada used for lessons.
• Part 15 and Part 19 links use confirmed series slugs.
• Word count and keyword density calculations count visible body text only (exclude metadata and References).

Where This Fits in Parts 1–18

• Part 1 — foundation for drug legalization and drug policy reform
• Part 1.5 — definitions
• Part 2 and Part 3 — underclass and rights costs
• Part 4 and Part 5 — what regulation buys
• Part 6 — unstable supply
• Part 7 — funding treatment on demand
• Part 8 and Part 18 — fear vs public health
• Part 9 and Part 14 — tiered model
• Part 10 — accountability and public safety
• Part 11 — evidence-based prevention
• Part 12 and Part 13 — reentry and stability
• Part 15 — hard objections
• Part 16 and Part 17 — pilot programs and case studies

The Myth That Regulation Is Too Complex to Run

When people say regulation is too complex, they usually mean one (or all) of these fears:

• the system will be gamed
• diversion control will fail
• bureaucracy will crush speed and common sense
• public safety will be sacrificed for ideology

Those concerns deserve answers. But none of them is unique to drug policy.

Every safety system can be gamed. We still run aviation safety, food safety, and pharmaceutical safety because the alternative is worse.

The “alternative” in drugs is not simplicity. It’s a complex, violent market with no labeling, no recall capacity, and no quality control — plus a criminal system that produces permanent consequences (Part 2 and Part 3) while failing to stabilize supply (Part 6). That is complexity too. It’s just unmanaged complexity.

The adult move is to replace unmanaged complexity with managed complexity: public health drug regulation that focuses enforcement on harm, not on possession theater.

That fits with Part 10: accountability doesn’t disappear; it changes target.

In a regulated model, enforcement is still aggressive where there are victims:

• sales to minors
• violence and coercion
• adulteration and fraud
• impaired driving
• organized diversion

So “too complex” is not really a warning about capability. It’s a warning about political risk — which is why this series keeps returning to pilot programs and policy evaluation (Part 16).

This Is Already Being Administered: The Systems We Run Today

The myth dies when you list what already exists.

Controlled substances recordkeeping is routine. Federal rules require registrants to keep inventories and records and make them available for inspection for at least two years; pharmacies must maintain Schedule II records separately from other pharmacy records.[2]

FDA risk management is routine. FDA requires Risk Evaluation and Mitigation Strategies (REMS) for certain drugs with serious safety concerns,[4] and FDA conducts inspections and can pursue enforcement actions for noncompliance.[5]

Opioid Treatment Programs are regulated systems. SAMHSA’s revised 42 CFR Part 8 final rule updates the regulations that guide OTPs and explicitly aims to expand access to high-quality, evidence-based care.[3]

PDMP infrastructure is administered statewide. CDC describes PDMPs as electronic databases tracking controlled substance prescriptions, used to support clinical safety decisions and identify overdose risk.[6]

Harm reduction implementation is also administered infrastructure. CDC summarizes nearly 30 years of evidence that comprehensive syringe services programs are safe and do not increase illegal drug use or crime.[8] FDA approved the first over-the-counter naloxone nasal spray in 2023,[9] and CDC notes naloxone can be obtained OTC and through community programs.[10]

This is what “already administered” looks like in plain terms:

System already operating	What it does	Who administers it	Built-in compliance	Lesson for scaling regulation
Controlled substance recordkeeping	Inventory + records + inspection availability.[2]	DEA framework + state oversight (pharmacy boards)	Retention rules; separate Schedule II records.[2]	High-compliance supply chains are possible.
FDA REMS programs	Extra safeguards for high-risk meds.[4]	FDA	Inspections; enforcement actions for failures.[5]	High-risk products already require tighter lanes.
OTPs for OUD treatment	Structured MOUD delivery standards.[3]	SAMHSA/HHS + accreditation/certification	Program standards + oversight	We already operate a high-structure opioid lane.
PDMPs	Track controlled prescribing statewide.[6]	States, used by clinicians	Cross-provider visibility; risk identification	Regulatory data systems already exist.
Harm reduction services	Reduce death/disease; link to care.[8][10]	Public health + community partners	Protocols, safe disposal, integration	Harm reduction implementation is administrable.

If someone says “we can’t administer regulation,” this table is the reply. We already do.

Public Health Drug Regulation: What It Means Operationally

Public health drug regulation is not a vibe. It’s an operating model.

It means:

• set standards that reduce unpredictability and death
• build monitoring that detects drift early
• enforce rules that protect public safety
• build treatment on demand so “help” is not a voicemail
• publish outcomes so the public can judge performance

This is where Part 9 matters. Risk-based drug regulation is the main way to avoid one-rule-for-everything stupidity.

In a risk-based system, the lanes differ:

• Lower-risk lane: licensed retail, age-gates, testing, packaging, penalties for sales to minors.
• Highest-risk lane: clinical access with the regulated pharmacy model, tight controls, and constant monitoring.

And because public health drug regulation sits in the real world, it must also deal with stigma and privacy. HHS states entities covered by the updated 42 CFR Part 2 requirements had to comply by February 16, 2026.[11] Whether you like Part 2 or hate it, it proves the system already administers complex confidentiality rules. The question is whether we can administer them while expanding treatment on demand. We can — if we choose to.

This is what Part 18 argued at the framing level: public health, not moral panic.

Regulated Pharmacy Model: The High-Risk Lane We Already Know How to Run

The regulated pharmacy model is the strongest answer to “regulation is too complex” because it starts from the highest-compliance environment we already operate.

Pharmacies already manage controlled substances under strict recordkeeping and inspection rules.[2] Many pharmacies interact with PDMP workflows.[6] Some medications come with REMS requirements.[4][5]

So the regulated pharmacy model is not “invent a new system.”

It is that existing system plus explicit goals: overdose prevention, diversion control, and treatment on demand.

In practical terms, a regulated pharmacy model lane should be built around:

Narrow eligibility

• high risk, high likelihood of prior exposure, clear medical risk markers

Standardization

• consistent product where possible, consistent dosing guidance, clear labeling

Tight diversion control

• identity verification, quantity limits, audit triggers, witnessed dosing where risk demands it

Clinical integration

• automatic offers of medication for opioid use disorder access
• rapid linkage to housing, mental health, and recovery supports (Part 13)

Accountability

• licensing sanctions for providers/sites that violate the rules
• targeted enforcement against coercion, fraud, and trafficking

International drug regulation case studies support the logic of a narrow high-structure lane.

In Switzerland’s heroin-assisted treatment, heroin prescription was developed for treatment-resistant opioid dependence and analyzed as an example of policy change managed through a structured process.[12]

That is the point: high-risk access works best when it is tightly administered, not when it is romanticized.

Medication for Opioid Use Disorder Access: The Bottleneck That Proves We’re Choosing Failure

If regulation were truly unmanageable, we wouldn’t be able to run complex opioid treatment systems at all.

But we do.

SAMHSA administers federal OTP regulations and updated 42 CFR Part 8 to expand access and improve quality.[3]

The problem is that medication for opioid use disorder access is still far too rare and far too slow.

CDC’s 2024 MMWR found that among adults needing OUD treatment in 2022:

• 25% received medications for OUD
• 30% received treatment without medications[7]

That implies 45% got no OUD treatment.

That is not “the complexity of regulation.” That is a systems bottleneck we are tolerating.

Category	Percent (Adults needing OUD treatment, 2022)
Received medications for OUD	25%
Received OUD treatment without medications	30%
Received no OUD treatment	45%

Source: CDC MMWR.[7]

If you want fewer funerals, medication for opioid use disorder access has to become routine, fast, and measurable.

This connects to the reentry risk window (Part 12) and the reality that instability and homelessness turn access barriers into death sentences (Part 13).

That is treatment on demand: not “here’s a number,” but “you start today.”

Harm Reduction Implementation: Evidence, Workflows, and Public Safety

People talk about harm reduction implementation as ideology. It’s mostly implementation — a logistics problem with a stigma problem on top.

Naloxone is a clean example. FDA approved the first OTC naloxone nasal spray in 2023.[9] CDC states naloxone is available OTC and can also be obtained through community programs and most syringe services programs.[10]

That is harm reduction implementation at scale.

Syringe services programs are another example. CDC summarizes nearly 30 years of research that comprehensive SSPs are safe, effective, cost-saving, and do not increase illegal drug use or crime.[8]

And supervised consumption is not a fantasy either. EUDA describes drug consumption rooms as facilities aiming to reduce disease transmission risks, prevent overdose deaths, and connect high-risk users with treatment and other services.[13] A Lancet study reported a significant reduction in overdose mortality in the area around Vancouver’s supervised injecting facility after it opened.[14]

You do not have to support every site in every neighborhood to accept the central point: harm reduction implementation is administrable — and the evidence base is real.

The key is integration:

• harm reduction implementation should be a bridge into medication for opioid use disorder access
• overdose prevention should be measured
• diversion control should be monitored
• accountability should be real
• public safety enforcement should target violence and exploitation, not possession theater (Part 10)

If you want the fear framing and why it fails, that’s Part 8.

Drug Regulation Case Studies and a Rollout Timeline That Doesn’t Lie

If you want “proof we can run complex regulation,” you don’t need new legislation to see it. You need to look honestly at existing drug regulation case studies:

• pharmacy recordkeeping and inspections[2]
• PDMP systems used in clinical practice[6]
• OTP regulation under 42 CFR Part 8[3]
• FDA REMS programs with inspections and enforcement[4][5]
• harm reduction services administered by public health and community partners[8][10]

Internationally:

Portugal administers its decriminalization framework through administrative processing and health-oriented responses.[15] (Part 17 covered the case study angle.)

Canada administers “safer supply” as prescribed medications intended to reduce risks from the toxic illegal supply; eligibility varies by program.[16] British Columbia tightened policy by requiring witnessed dosing of prescribed alternatives to help prevent diversion to illicit markets.[17]

And yes, failures belong in the record too. Oregon’s Measure 110 audit is a drug regulation case study in governance breakdown: it emphasized lack of stability, coordination, and clear results.[18] That is not proof that regulation can’t be administered. It’s proof that pilot programs without clear policy evaluation, ownership, and dashboards get crushed.

gantt
    title Part 19: Regulation Is Already Being Administered — Rollout Stages
    dateFormat YYYY-MM-DD
    section Stabilize the basics
    PDMP workflow improvements :a1, 2026-04-01, 90d
    OTC naloxone saturation + distribution partners :a2, 2026-04-01, 90d
    SSP expansion + safe disposal :a3, 2026-04-15, 120d
    section Fix the bottleneck
    Medication for opioid use disorder access (same-day starts) :b1, 2026-05-15, 180d
    OTP modernization support (Part 8 adoption) :b2, 2026-05-15, 180d
    section Pilot the high-risk lane
    Regulated pharmacy model pilot :c1, 2026-09-01, 180d
    Diversion control monitoring + audit triggers :c2, 2026-09-01, 180d
    section Decide
    Quarterly policy evaluation + public dashboard :d1, 2026-10-01, 365d
    Scale / tighten / stop gate :d2, 2027-10-01, 30d

This is what “administrable” looks like: start with what already exists, pilot what is controversial, measure outcomes, and scale only what works.

Frequently Asked Questions

Isn’t public health drug regulation just a bigger bureaucracy?

It can turn into one if you don’t tie it to measurable outcomes. The point here is that public health drug regulation is already being administered in pieces: pharmacies, PDMPs, OTPs, REMS programs, and harm reduction infrastructure.[2][3][4][6]

How does the regulated pharmacy model handle diversion control?

It handles diversion control the same way other high-risk systems do: identity verification, limits, audits, and tightening protocols when risk rises. British Columbia’s shift to witnessed dosing for prescribed alternatives is a real-world example of tightening to prevent diversion to illicit markets.[17]

What is the single biggest “do this first” recommendation?

Medication for opioid use disorder access. CDC’s estimate that only 25% of adults needing OUD treatment in 2022 received medications should be treated as a national failure metric.[7]

Does harm reduction implementation undermine public safety?

CDC summarizes decades of evidence that SSPs do not increase crime.[8] OTC naloxone availability and community distribution are also public safety tools because they prevent deaths that would otherwise occur before EMS arrives.[10]

How do you keep reforms from collapsing politically?

Pilot programs plus policy evaluation plus dashboards. Oregon’s audit is a warning: if you can’t show outcomes clearly, reform becomes a narrative war you lose.[18]

References

[1] Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Drug Overdose Deaths in the United States, 2023–2024 (NCHS Data Brief No. 549). https://www.cdc.gov/nchs/products/databriefs/db549.htm

[2] Electronic Code of Federal Regulations (eCFR). 21 CFR 1304.04 — Maintenance of records and inventories. https://www.ecfr.gov/current/title-21/chapter-II/part-1304/subject-group-ECFR64b4002fc681198/section-1304.04

[3] Substance Abuse and Mental Health Services Administration (SAMHSA). 42 CFR Part 8 Final Rule (Opioid Treatment Programs). https://www.samhsa.gov/substance-use/treatment/opioid-treatment-program/42-cfr-part-8

[4] U.S. Food and Drug Administration (FDA). Risk Evaluation and Mitigation Strategies | REMS. https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems

[5] U.S. Food and Drug Administration (FDA). REMS Compliance Program. https://www.fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/rems-compliance-program

[6] Centers for Disease Control and Prevention (CDC). Prescription Drug Monitoring Programs (PDMPs). https://www.cdc.gov/overdose-prevention/hcp/clinical-guidance/prescription-drug-monitoring-programs.html

[7] Centers for Disease Control and Prevention (CDC). Treatment for Opioid Use Disorder: Population Estimates (MMWR, 2024). https://www.cdc.gov/mmwr/volumes/73/wr/mm7325a1.htm

[8] Centers for Disease Control and Prevention (CDC). Strengthening Syringe Services Programs (SSPs). https://www.cdc.gov/hepatitis-syringe-services/php/about/index.html

[9] U.S. Food and Drug Administration (FDA). FDA Approves First Over-the-Counter Naloxone Nasal Spray (GovDelivery bulletin, Mar 29, 2023). https://content.govdelivery.com/accounts/USFDA/bulletins/351b34d

[10] Centers for Disease Control and Prevention (CDC). Lifesaving Naloxone | Stop Overdose. https://www.cdc.gov/stop-overdose/caring/naloxone.html

[11] U.S. Department of Health and Human Services (HHS). Fact Sheet: 42 CFR Part 2 Final Rule. https://www.hhs.gov/hipaa/for-professionals/regulatory-initiatives/fact-sheet-42-cfr-part-2-final-rule/index.html

[12] Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction (2010) (PubMed). https://pubmed.ncbi.nlm.nih.gov/19922519/

[13] European Union Drugs Agency (EUDA). Drug consumption rooms: an overview of provision and evidence (Perspectives on drugs). https://www.euda.europa.eu/publications/pods/drug-consumption-rooms_en

[14] The Lancet. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study (2011) (abstract). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2962353-7/abstract

[15] SICAD (Portugal). Decriminalisation Law (overview PDF). https://sicad.pt/BK/Publicacoes/Lists/SICAD_PUBLICACOES/Attachments/94/DesdobravelDescriminalizacao_PT_EN.pdf

[16] Health Canada. Safer supply: Prescribed medications as a safer alternative to toxic illegal drugs. https://www.canada.ca/en/health-canada/services/opioids/responding-canada-opioid-crisis/safer-supply.html

[17] Government of British Columbia. Prescribed alternatives — witnessed dosing. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/pharmacare-substance-use-disorder-hub/pa

[18] Oregon Secretary of State Audits Division. Oregon Health Authority: Measure 110 Lacks Stability, Coordination, and Clear Results (Report 2025-29). https://sos.oregon.gov/audits/Documents/2025-29.pdf

Previous Next